Back HIV Populations Women & HIV

Women & HIV

Human Papillomavirus Vaccine Is Effective for Women with HIV

HIV positive women respond well to the Gardasil human papillomavirus (HPV) vaccine, offering them protection against cervical cancer, according to a study published in the April 14 electronic edition of Clinical Infectious Diseases. Related recent research found that both Gardasil and Cervarix are effective in people with HIV.

alt

Read more:

New Recommendations for Earlier HIV Screening and PrEP for Women

The American College of Obstetricians and Gynecologists last week issued 2 new recommendations on screening and prevention of HIV in women. The first matches the CDC's recommendation that HIV screening should start at age 13 and should be offered at least annually to at-risk women. The second advises that pre-exposure prophylaxis (PrEP) -- using antiretroviral medications such as Truvada to prevent HIV infection -- may be a useful tool for women at highest risk, including those with HIV positive male partners.

alt

Read more:

GRACE Survey Sheds Light on Treatment Benefits and Barriers for HIV+ Women

Caring for children, unemployment, and transportation difficulties were among the factors most likely to lead to poor adherence, early dropout, and suboptimal response to antiretroviral therapy (ART) among participants in the GRACE trial, which tested darunavir (Prezista) in a study population consisting largely of women of color. Overall, they said participation was a positive experience and they would encourage others to join a clinical trial.

alt

Read more:

HIV+ Women May Experience More Severe Menopause Symptoms

Women with HIV on average experience more severe hot flashes around the time of menopause than HIV negative women, and they interfere more with daily life, according to a study described in the July 1, 2013, advance online edition of the journal Menopause.

alt

Read more:

New Advocacy Group Wants to Improve Feasibility of PrEP for U.S. Women

Following disappointing results from the VOICE trial released at the recent 20th Conference on Retroviruses and Opportunistic Infections (CROI) in Atlanta, a new U.S. Women and PrEP Working Group has called on the federal government to help American women use antiretroviral pre-exposure prophylaxis (PrEP) safely and effectively. But the AIDS Healthcare Foundation (AHF) responded by urging the Food and Drug Administration to rescind its approval of Truvada (tenofovir/emtricitabine) for HIV prevention.

alt

Read more: